News

Published on 14 Feb 2024 on Zacks via Yahoo Finance

Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?


Article preview image

Galecto, Inc. (GLTO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.

NASDAQ.GLTO price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Galecto, Inc. (GLTO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank...

Zacks via Yahoo Finance 14 Feb 2024

What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock

Galecto, Inc. (GLTO) could be a solid choice for investors given its recent upgrade to a Zacks Ra...

Zacks via Yahoo Finance 9 Jan 2024

OrbiMed Advisors LLC Reduces Stake in Galecto Inc

OrbiMed Advisors LLC, a renowned investment firm, recently executed a significant transaction inv...

GuruFocus.com via Yahoo Finance 17 Aug 2023

Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More

It was a low-key week for the biotech sector as the earnings season ended and nothing much came f...

Zacks via Yahoo Finance 17 Aug 2023

Galecto (GLTO) Down 71% as Lung Disease Candidate Fails

Galecto’s GLTO mid-stage study evaluating inhaled GB0139 for treatment of idiopathic pulmonary fi...

Zacks via Yahoo Finance 16 Aug 2023

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.02% By Investing.com

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.02%

Investing.com 15 Aug 2023

Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day...

Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day...

Investing.com 15 Aug 2023

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Shares of Galecto Inc. dropped 65% in premarket trading Tuesday after the biotech company said it...

Market Watch 15 Aug 2023

ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc

On July 25, 2023, ORBIMED ADVISORS LLC (Trades, Portfolio), a renowned investment firm, reduced i...

GuruFocus.com via Yahoo Finance 27 Jul 2023

These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts

Since the beginning of January, we’ve seen a steady rise in the stock markets. The NASDAQ is up 3...

TipRanks via Yahoo Finance 25 Jul 2023